XELLIA PHARMACEUTICALS ApS: Financial statements 2020
CVR: 61094628
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 2,042,515,000 and a net result of DKK -115,666,000 compared with DKK 390,722,000 the year before. That is a decrease of 12.9% compared with the year before. The profit margin was -5.7%. Equity in the 2020 report amounted to DKK 2,621,030,000. The solvency ratio was 64.1%. The company had 624 employees in the financial year.
- Revenue
- DKK 2,042,515,000
- Gross Profit
- DKK 361,330,000
- Profit/Loss
- DKK -115,666,000
- Equity
- DKK 2,621,030,000
- Total Assets
- DKK 4,090,943,000
- Employees
- 624
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 2B | 361.3M | -115.7M | 2.6B | 624 |
| 2019 | 2.3B | 873.5M | 390.7M | 1.4B | 623 |
| 2018 | 1.9B | 576.7M | -74.9M | 1B | 580 |
| 2017 | 1.9B | 528.3M | 91M | 850.8M | 493 |
| 2016 | 1.5B | 521.8M | 33.8M | 758.8M | 466 |
Official annual report
How creditworthy is XELLIA PHARMACEUTICALS ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
XELLIA PHARMACEUTICALS ApS has published its annual report for 2019. Revenue came to DKK 2,346,296,000, and the net result was DKK 390,722,000.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.